Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer: later-stage trial registry
1 of 3 indexed Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer: 3 US clinical trials tracked, 1 recruiting.
Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Astellas Pharma Global Development, running 3 of these trials.
Enrollment posture brief
Registry condition locally-advanced-unresectable-gastric-adenocarcinoma-or-cancer
OPEN 1 | RECR 33% | LATE 3 | EARLY 0 | RANK #5209 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer is recruiting below its size-band peers.
1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Astellas Pharma Global Development
NCT06901531
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
Astellas Pharma Global Development
NCT03504397
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
Astellas Pharma Global Development
NCT03653507
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer page
3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Astellas Pharma Global Development sponsors the most Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer trials on record, review their full trial history before evaluating a specific study. See Astellas Pharma Global Development's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer condition card totals 3 registered trials; most-linked intervention zolbetuximab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.